ArticleScientific reports2025
Anti-IgD nanobodies as novel tools for studying human IgD biology.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
IgD is the least well characterized of mammalian antibody isotypes and its biology remains poorly understood. Nanobodies are a useful and versatile tool for research and diagnostics, including for protein purification, capture and detection applications. Here we report the characterization of four anti-human IgD nanobodies, specific to the Fc region of IgD. The four nanobodies bound to human IgD with low nanomolar affinity, showing different binding kinetics and interaction stoichiometries, as well as recognizing four distinct epitopes. We found one of these anti-IgD nanobodies, aδNb408, to be an excellent purification tool for IgD, with efficient capture and elution at pH 3.5. To aid the analysis of IgD interactions using surface plasmon resonance, we identified two nanobodies that provided good capture of IgD. Assembling bispecific and bivalent nanobody pairs increased the avidity of the anti-IgD nanobodies, with the bispecific nanobody pair aδNb408-aδNb107 showing robust detection of IgD on Namalwa B cells. The anti-IgD nanobody tools described here can be used for diverse applications that have the potential to further our understanding of IgD biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.